Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation-Reference-Cited by-同舟云学术

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

Published:2018-01-31 Issue:5 Volume:32 Page:1239-1243
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Correnti Colin E.,Laszlo George S.,de van der Schueren Willem J.,Godwin Colin D.,Bandaranayake Ashok,Busch Melanie A.,Gudgeon Chelsea J.,Bates Olivia M.,Olson James M.,Mehlin Christopher,Walter Roland B.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0014-3.pdf

Reference15 articles.

1. Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun. 2012;12:12.

2. Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101:634–45.

3. Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–12.

4. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.

5. von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381–89.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-cell exhaustion in multiple myeloma;Expert Review of Hematology;2024-06-26

2. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-06

3. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31

4. Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager;Nature Biomedical Engineering;2024-05-01

5. Bispecific antibodies for multiple myeloma: past, present and future;International Journal of Hematology;2024-04-13